Corline Biomedical Q2: Kardium’s Globe system nearing launch - Redeye

Redeye provides an update following Corline’s Q2 2025 report. Overall, the report contained no major surprises, with sales remaining at relatively low levels and costs under control. Following the report, we have made only minor adjustments to our estimates, leaving our valuation unchanged.

Länk till analysen i sin helhet: https://www.redeye.se/research/1125102/corline-biomedical-q2-kardiums-globe-system-nearing-launch?utm_source=finwire&utm_medium=RSS